Early TNF Inhibitor Use Improves Outcomes in Nonsystemic JIA
Early initiation of TNF inhibitors among children with non-sJIA led to significant and sustained improvements in disease activity.
According to study results presented at the American College of Rheumatology (ACR) Convergence 2025, early initiation of tumor necrosis factor (TNF) inhibitor therapy among children diagnosed with nonsystemic juvenile idiopathic arthritis (non-sJIA) when aged 2 years or less leads to significant and sustained improvements in disease activity.
Using data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry from 2015 to 2023, researchers aimed to describe the demographic and disease characteristics of children diagnosed with non-sJIA when aged from 0 to 23 months.
Author's summary: Early TNF inhibitor use improves nonsystemic JIA outcomes.
More News
- Pirates Top 30 Prospects No. 15: Zander Mueth Set Back By Injuries
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- The environmental impact of the 2026 World Cup
- D&H Distributing’s Advanced Solutions Plus Unit To Focus On The Enterprise, ‘A Pivotal Evolution’ For Its Business
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents
- Deandre Ayton claims Los Angeles Lakers superstars ‘troll him’ to get him going
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- Rutgers Health and University Hospital Break Ground on First Phase of Sweeping Newark Campus Redevelopment
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow